Here's Why bluebird bio's Shares Soared 24% in November
After bluebird bio (NASDAQ: BLUE) updated investors on the presentations it will be making at a key industry conference soon, its shares jumped 24.2% in November, according to S&P Global Market Intelligence.
The company is on the cutting edge of gene-therapy research, and in November, management unveiled data that it will be presenting this month at the high-profile American Society of Hematology conference, which runs from December 9 to December 12.
IMAGE SOURCE: GETTY IMAGES.
Source: Fool.com
Bluebird Bio Inc. Aktie
Die Community ist sich nicht einig: Bluebird Bio Inc. hat genauso viele Buy- wie Sell-Einschätzungen.
Die Community prognostiziert für Bluebird Bio Inc. ein Kursziel von 5 €, was den aktuellen Kurs von 0.54 € weit übertrifft.